What is the typical disease course of immune thrombocytopenic purpura (ITP) and its treatment approach in children compared to adults?

Disease Course of Immune Thrombocytopenic Purpura (ITP)

ITP follows fundamentally different disease trajectories in children versus adults: children typically experience an abrupt, self-limited course with spontaneous resolution within weeks to months, while adults develop an insidious, chronic disease requiring long-term management. 1

Children: Self-Limited Disease Course

Natural History

• Peak incidence occurs at 2-4 years of age with equal distribution between boys and girls 2, 3
• The disease onset is typically abrupt and often follows a viral infection 4, 5
• Spontaneous recovery occurs in several weeks to several months in most children 4, 3
• Infants (1-12 months) have an even more benign course, with thrombocytopenia resolving at a mean of 1.90 months after diagnosis 6

Progression to Chronic Disease

• Only a minority of children develop chronic ITP (defined as lasting >12 months) 1
• Infants are particularly unlikely to develop chronic disease compared to toddlers (1/22 vs. 9/30, P = 0.032) 6
• Most children present with minor or mild bleeding (86.4% in infants) and seldom require treatment (31.8%) 6

Treatment Approach in Children

• Observation is recommended over IVIg for children with newly diagnosed ITP who have no or minor bleeding 7, 1
• Treatment is reserved for those with significant bleeding or diminished quality of life 1
• Splenectomy should be delayed for ≥12 months unless disease is severe and refractory, as spontaneous remission remains possible 1

Adults: Chronic, Insidious Disease Course

Natural History

• Most common among young women with an insidious onset 2, 3
• The disease is persistent, often lasting many years or characterized by recurrent exacerbations 2
• Adults typically run a chronic course lasting >6 months and are often resistant to conventional treatment 8
• The natural history and long-term prognosis remain incompletely defined 2

Disease Phases and Treatment Evolution

Newly Diagnosed ITP (First 3 Months)

• Initiate corticosteroids (prednisone 0.5-2 mg/kg/day or dexamethasone 40 mg/day for 4 days) when platelet count is <30 × 10⁹/L 1
• Add single-dose IVIg (1 g/kg) to corticosteroids when rapid platelet rise is needed for active bleeding or urgent surgery 1
• Avoid combining rituximab with corticosteroids as initial therapy due to insufficient evidence of benefit 7, 1

Persistent ITP (3-12 Months)

• TPO-RAs (romiplostim or eltrombopag) are preferred over rituximab for corticosteroid-dependent or non-responsive patients 7, 1
• Delay splenectomy during the first year because spontaneous remission remains possible 1
• Rituximab may be considered for patients who cannot afford TPO-RAs or strongly prefer to avoid long-term medication 1

Chronic ITP (≥12 Months)

Treatment selection depends on patient priorities 1:

• For patients prioritizing avoidance of long-term medication: Rituximab is preferred over splenectomy despite lower durability 1
• For patients prioritizing avoidance of surgery: TPO-RAs are preferred over rituximab due to superior durability 1
• For patients prioritizing durable response: Either splenectomy or TPO-RA is acceptable based on willingness for surgery versus chronic medication 1

Post-Splenectomy Course

• Splenectomy increases platelet counts in hours to days in most patients 8
• However, nearly 50% experience recurrent thrombocytopenia by 5 years post-splenectomy 8
• TPO-RAs are strongly recommended for relapse after splenectomy 1
• Do not treat asymptomatic patients with platelet counts >30 × 10⁹/L after splenectomy 1

Key Pathophysiologic Differences

Mechanism of Disease

• Both children and adults experience antibody-mediated platelet destruction via Fc receptor binding on macrophages, resulting in accelerated platelet consumption primarily in the spleen 2
• Increased megakaryocyte production attempts to compensate for peripheral destruction 8
• When compensation fails, thrombocytopenia and characteristic bleeding tendency (purpura) develop 8

Critical Mortality Considerations

Intracerebral hemorrhage, while rare, is the most common cause of death in both children and adults with ITP 2. This underscores the importance of maintaining safe platelet counts despite the generally benign course in children.

Common Pitfalls

• Do not perform routine bone marrow examination in patients with typical ITP, regardless of age 1
• Do not rush to splenectomy within the first year in either children or adults, as spontaneous remission remains possible 1
• Avoid routine upfront combination of rituximab with corticosteroids—evidence of benefit is insufficient 7, 1
• Tests for antiplatelet antibodies have not been established as clinically useful for management decisions 2